Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.

Lipika  Goyal

Consulting or Advisory Role - Agios; Alentis Therapeutics; AstraZeneca; Debiopharm Group; Exelixis; Genentech; H3 Biomedicine; Incyte; Klus Pharma; QED Therapeutics; Sirtex Medical; Taiho Pharmaceutical

(OPTIONAL) Uncompensated Relationships - Agios; Debiopharm Group; Merck; Taiho Pharmaceutical

Funda  Meric-Bernstam

Employment - MD Anderson Cancer Center

Consulting or Advisory Role - Abbvie; AstraZeneca; Biovica; Black Diamond Therapeutics; Debiopharm Group; eFFECTOR Therapeutics; Eisai; Infinity Pharmaceuticals; Karyopharm Therapeutics; Kolon Life Sciences; Lengo Therapeutics; Loxo; OnCusp Therapeutics; PACT Pharma; Roche; Seagen; Silverback Therapeutics; Tallac Therapeutics; Tyra Biosciences; Xencor; Zentalis; Zymeworks

Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)

Antoine  Hollebecque

Honoraria - Amgen; Eisai; Incyte; Relay Therapeutics; SERVIER

Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Spectrum Pharmaceuticals (Inst)

Research Funding - AstraZeneca/MedImmune (Inst)

Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Roche; SERVIER

Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor

Chigusa  Morizane

Honoraria - Eisai; MSD K.K.; Novartis; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha

Consulting or Advisory Role - MSD K.K.; SERVIER; Yakult Honsha

Research Funding - AstraZeneca (Inst); Daiichi Sankyo RD Novare; Eisai (Inst); Hitachi (Inst); J-Pharma (Inst); Merck (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)

Juan W.  Valle

Consulting or Advisory Role - Aptitude Health; AstraZeneca; Autem Medical; Baxter; Cantargia AB; Debiopharm Group; Genoscience Pharma; Hutchison MediPharma; Imaging Equipment Limited; Incyte; Ipsen; Keocyt; Medivir; Merck; Mundipharma; Novartis; Nucana; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics; SERVIER; Sirtex Medical; Taiho Oncology; Wren Laboratories; Zymeworks

Speakers' Bureau - Delcath Systems; Imaging Equipment Limited; Incyte; Ipsen; Mylan; Novartis; Nucana; SERVIER

Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Lilly; Nucana; Roche

Thomas Benjamin  Karasic

Honoraria - AstraZeneca/MedImmune; Exelixis; Incyte; Ipsen; Pfizer

Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); H3 Biomedicine (Inst); Lilly (Inst); Sirtex Medical (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst); Tempest Therapeutics (Inst); Xencor (Inst)

Thomas Adam  Abrams

Stock and Other Ownership Interests  - Guardant Health; Jounce Therapeutics; Mirati Therapeutics

Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Lilly; Merck; SERVIER

Robin Kate  Kelley

Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exact Sciences; Exelixis/Ipsen (Inst); Genentech/Roche; Gilead Sciences; Kinnate Biopharma; Merck (Inst)

Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo/Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)

Travel, Accommodations, Expenses - Ipsen

Philippe Alexandre  Cassier

Honoraria - Amgen; ITeos Therapeutics; Janssen

Consulting or Advisory Role - OSE Immunotherapeutics

Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)

Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Merck Serono; Merck Sharp & Dohme; Netris Pharma; Roche

Junji  Furuse

Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD; Mylan; Nihon Servier; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Merck; MSD; Mundipharma; OncoTherapy Science; Ono Pharmaceutical; Takara Bio; Yakult Honsha

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); J-Pharma (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)

Heinz-Josef  Klümpen

No Relationships to Disclose

Heung-Moon  Chang

Research Funding - Astellas Pharma (Inst); Celgene (Inst); Taiho Oncology (Inst); Zymeworks (Inst)

Li-Tzong  Chen

Stock and Other Ownership Interests  - ScinoPharm

Honoraria - Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; SynCoreBio; TTY Biopharm

Consulting or Advisory Role - AstraZeneca Canada; Bristol-Myers Squibb; CStone Pharmaceuticals; Ipsen; Lilly; MSD; Ono Pharmaceutical; Onward Therapeutics; Taivex Therapeutics

Research Funding - ACT Genomics; Celgene; Novartis; OBI Pharma; Pfizer; Polaris; SyncoreBio; TTY Biopharm

Patents, Royalties, Other Intellectual Property - HuniLife Taiwan

Yoshito  Komatsu

Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Oncology

Research Funding - Chugai Pharma; Daiichi Sankyo; IQVIA; Ono Pharmaceutical; Taiho Oncology

Kunihiro  Masuda

No Relationships to Disclose

Daniel H.  Ahn

Stock and Other Ownership Interests  - Natera

Consulting or Advisory Role - Advanced Accelerator Applications; Daiichi Sankyo/Astra Zeneca; Eisai; Exelixis; Genentech/Roche; Novartis

Research Funding - AstraZeneca; Bayer

Kate  Li

Employment - Taiho Oncology

Travel, Accommodations, Expenses - Taiho Oncology

Karim A.  Benhadji

Employment - Lilly; Taiho Oncology

Stock and Other Ownership Interests  - Lilly

Volker  Wacheck

Employment - Lilly; Taiho Oncology

Stock and Other Ownership Interests  - Lilly; Taiho Oncology

Patents, Royalties, Other Intellectual Property - Patent (Inst)

John A.  Bridgewater

Honoraria - Merck Serono; SERVIER

Consulting or Advisory Role - AstraZeneca; Basilea; Bayer; Incyte; Merck Serono; Merck Serono; Roche; SERVIER; Taiho Oncology

Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene

Research Funding - Amgen; Incyte (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Merck Serono; MSD Oncology; SERVIER